EMBC — Embecta Corp.

Summary of Embecta Corp. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Approximately $261 million, a 0.3% decline year-over-year (2% decline on an adjusted constant currency basis).
  • US Revenue: $131 million, down 7.6% year-over-year (adjusted constant currency).
  • International Revenue: $130 million, up 8.4% reported (4.6% adjusted constant currency), driven by EMEA and Latin America.
• Gross Profit: GAAP gross profit of $161.7 million (61.9% margin); adjusted gross profit of $163.5 million (62.6% margin).
• Operating Income: GAAP operating income of $83.3 million (31.9% margin); adjusted operating income of $79.3 million (30.4% margin).
• Net Income: GAAP net income of $44.1 million ($0.74 per diluted share); adjusted net income of $42.3 million ($0.71 per diluted share).
• Free Cash Flow: Generated approximately $17 million; $38 million of debt repaid, reducing net leverage to 2.8 times.

2. Strategic Updates and Business Highlights

• Strategic Roadmap: Transitioning from the "stand-up" phase to the "seed growth" phase, focusing on core competitiveness and portfolio expansion.
• Brand Transition: Over 95% of US and Canadian products have transitioned to the Embecta brand, with global transitions expected to be largely complete by the end of 2026.
• Medicare Part D: Secured exclusive access with an additional payer and renewed relationships with top three payers, enhancing market access.
• Portfolio Expansion: Advancing market-appropriate pen needles and syringes, with production validation underway.
• GLP-1 Strategy: Collaborating with over 30 pharmaceutical partners for co-packaging with generic GLP-1 therapies, with initial launches expected in 2026 in several markets.

3. Forward Guidance and Outlook

• Revenue Guidance: Reaffirmed guidance for 2026, expecting revenue to be flat to down 2% compared to 2025, leaning towards the lower end due to US pricing pressures.
• Adjusted Operating Margin: Expected to be between 29-30%; adjusted EPS guidance remains between $2.80 and $3.00, also leaning towards the lower end.
• Debt Repayment: Anticipating approximately $150 million in debt repayment and free cash flow generation of $180 million to $200 million, closer to the low end.

4. Bad News, Challenges, or Points of Concern

• US Revenue Decline: Notable 7.6% decline in US revenue attributed to lower pricing and volume, influenced by channel dynamics.
• China Market Headwinds: Continued challenges in the Chinese market, with recovery expected to be more weighted towards the second half of the fiscal year.
• Pricing Pressures: Incremental headwinds from pricing dynamics leading to a cautious outlook on revenue guidance.
• Contract Manufacturing Decline: Revenue from contract manufacturing down 16.7%, reflecting insourcing by Becton Dickinson.

5. Notable Q&A Insights

• US Market Dynamics: The decline in US revenue was attributed to a shift in customer and product mix, impacting pricing and volume.
• China Recovery: Initiatives in China are gaining traction, but the first half of the year is expected to remain challenging.
• GLP-1 Market: Confidence in the GLP-1 opportunity remains strong, with injectables expected to maintain relevance despite the rise of oral therapies.
• International Strength: Improved performance in EMEA and Latin America attributed to superior execution and new customer wins.

Overall, Embecta is navigating a challenging environment with strategic initiatives aimed at long-term growth, despite facing headwinds in pricing and specific market segments.